Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02912572 · ClinicalTrials.gov registry record · Phase 2
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
A Phase 2 study of Metastatic Endometrial Cancer, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
- 4
- Study locations
NCT02912572 is a Phase 2 study of Metastatic Endometrial Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 106 participants. The trial reports 4 study locations across 2 states.
The verdict
NCT02912572, a Phase 2 study of Metastatic Endometrial Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
- 4
- Study locations
Study Summary
This research study is evaluating a drug called Avelumab alone and in combination with Talazoparib or Axitinib as a possible treatment for recurrent or metastatic endometrial cancer.
Conditions Studied
Interventions
- DRUG Talazoparib
- DRUG Axitinib
- DRUG Avelumab
Study Locations (4)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana Farber Cancer Institute - Boston
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2016-11-14 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02912572
The ClinicalTrials.gov registry entry for NCT02912572 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Endometrial Cancer appearing as the primary indexed condition, and to 3 interventions - of which Talazoparib is the first listed.
NCT02912572 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Illinois.
Frequently Asked Questions
What is clinical trial NCT02912572 about?
NCT02912572 is a clinical study titled "Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer". This research study is evaluating a drug called Avelumab alone and in combination with Talazoparib or Axitinib as a possible treatment for recurrent or metastatic endometrial cancer.
What is the current status of trial NCT02912572?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2016-11-14. Estimated completion is 2026-11.
What conditions does trial NCT02912572 study?
This clinical trial studies the following conditions: Metastatic Endometrial Cancer.
What interventions are being tested in trial NCT02912572?
The interventions under investigation include: Talazoparib (DRUG), Axitinib (DRUG), Avelumab (DRUG).
Who is sponsoring clinical trial NCT02912572?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02912572 being conducted?
This trial has 4 study locations across Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.